Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | +8.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.23 | N/A | +8.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance, highlighting the importance of strategic planning. They did not provide specific guidance for the upcoming quarters.
Management emphasized the need for continued focus on cost management.
They acknowledged challenges in the current market environment.
Biocryst Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock fell 8.5% in reaction, likely due to the lack of revenue figures and no forward guidance. Investors may be concerned about the company's future performance amidst ongoing market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HONEYWELL INTL INC
Jul 27, 2009